| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 738.00 | 0.7% |
| Total Income | 758.00 | 0.0% |
| Expenditure | 770.00 | 1.3% |
| PBT | -109.00 | 395.4% |
| Net Profit | -108.00 | 140.0% |
| OPM | -3.39% | 12.00pp |
| NPM | -14.25% | 8.31pp |
| EPS | 5.53 | 252.2% |
Wockhardt Reports 1% QoQ Growth in Q1FY26, Showcases Progress in Novel Antibiotics and Biosimilars
08 Aug 2025 · 8 Aug 2025, 03:00 pm
Summary
Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 1st Quarter Results for Financial Year 2025-26. The company reported a 1% QoQ growth in EBITDA in Q1FY26. The company is focusing on profitability while balancing investments in innovative portfolio comprising Novel Antibiotics and Diabetes Biosimilars.
Key Highlights
- 1
Revenue for Q1FY26 is INR 738 Cr compared to INR 747 Cr in the previous year.
- 2
QoQ growth of 1% in EBITDA in Q1FY26, EBITDA for Q1FY26 of INR 101 Cr compared to INR 100 Cr in the previous year.
- 3
Global Phase III clinical study completed for ZAYNICH® (Zidebactam/Cefepime, WCK 5222).
- 4
Two pre-NDA meetings with US FDA have been successfully completed.
- 5
Filing of the New Drug Application (NDA) dossier is targeted in September 2025.
- 6
In India, the NDA has already been submitted on March 31, 2025.
- 7
Miqnaf® NAFITHROMYCIN, approved and launched on May 27 2025, in India.
- 8
Phase 3 study of WCK 4282 is slated to be completed in FY 25-26.
Management Comments
Not specified in the document
The business approach of the Company is to continue the growth momentum with focus on profitability while balancing investments in innovative portfolio comprising Novel Antibiotics and Diabetes Biosimilars to build an organization across various aspects of regulatory, clinical, medical and commercial excellence for pre-launch and launch activities in India and developed markets.
Informational and educational content only. Not investment advice.